NKG2D ligands

Erlotinib enhances the CIK cell-killing sensitivity of lung adenocarcinoma A549 cells

J. Z. Mei, Liu, G. J., Zhang, X. J., Zhao, J. Z., and Feng, R. T., Erlotinib enhances the CIK cell-killing sensitivity of lung adenocarcinoma A549 cells, vol. 14, pp. 3082-3089, 2015.

We examined the effects and molecular mechanism of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib on NKG2D ligand expression in human lung adenocarcinoma A549 cells and the cytotoxicity of cytokine-induced killer cells. Flow cytometry was used to detect NKG2D ligand expression in A549 cells under effects of erlotinib and EGFR downstream molecules, including LY294002 (phosphoinositide 3-kinase inhibitor), SB203580 (mitogen-activated protein kinase inhibitor), and STAT21 (signal transduction and transcription 3 inhibitor) after 24 h.

Subscribe to NKG2D ligands